Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 595 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR FDA Approves Enzalutamide for Non-Metastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence December 15, 2023 Brothers Start Nonprofit To Help Fellow Teens Struggling With Mental Health... December 30, 2021 Survivorship and Immune Checkpoint Inhibitors July 21, 2020 Your Microbiome and Cancer: What to Know December 23, 2020 Load more HOT NEWS Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line... Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally... Sleep Issue Called Hypersomnolence Can Increase The Risk Of Diabetes And... Colon capsule endoscopy – reshaping bowel cancer diagnosis
